The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

по Guastalla III, J P, Diéras, V
Опубликовано 2003

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

по Cortés, J., Curigliano, G., Diéras, V.
Опубликовано 2014

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

по Le Tourneau, C, Servois, V, Diéras, V, Ollivier, L, Tresca, P, Paoletti, X
Опубликовано 2012

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

по Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Опубликовано 2004

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

по Brandsma, D., Dieras, V., Altintas, S., Anders, C., Arnedos, M., Gelderblom, H., Soetekouw, P., Jager, A., van Linde, M., Aftimos, P.
Опубликовано 2014

Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study

по Loulergue, P, Alexandre, J, Iurisci, I, Grabar, S, Medioni, J, Ropert, S, Dieras, V, Le Chevalier, F, Oudard, S, Goldwasser, F, Lebon, P, Launay, O
Опубликовано 2011

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp...

по Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Опубликовано в: Ann Oncol (2015)

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Europe...

по Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P., Fumoleau, P.
Опубликовано 1996

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

по Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Опубликовано 2000

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

по Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Опубликовано 2014

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

по Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Опубликовано 2013

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

по Vincent-Salomon, A, Pierga, J-Y, Couturier, J, d'Enghien, C D, Nos, C, Sigal-Zafrani, B, Lae, M, Fréneaux, P, Diéras, V, Thiéry, J-P, Sastre-Garau, X
Опубликовано 2007

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

по Siegel-Lakhai, W S, Zandvliet, A S, Huitema, A D R, Tibben, M M, Milano, G, Girre, V, Diéras, V, King, A, Richmond, E, Wanders, J, Beijnen, J H, Schellens, J H M
Опубликовано 2008

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

по Brain, E, Isambert, N, Dalenc, F, Diéras, V, Bonneterre, J, Rezai, K, Jimenez, M, Mefti-Lacheraf, F, Cottura, E, Tresca, P, Vanlemmens, L, Mahier-Aït Oukhatar, C, Lokiec, F, Fumoleau, P
Опубликовано 2012

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

по Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Опубликовано 2005

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

по Rugo, H S, Diéras, V, Gelmon, K A, Finn, R S, Slamon, D J, Martin, M, Neven, P, Shparyk, Y, Mori, A, Lu, D R, Bhattacharyya, H, Bartlett, C Huang, Iyer, S, Johnston, S, Ettl, J, Harbeck, N
Опубликовано в: Ann Oncol (2018)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or meta...

по Emens, L.A., Adams, S., Barrios, C.H., Dieras, V.C., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Chui, S.Y., Schmid, P.
Опубликовано в: Ann Oncol (2020)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

по Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Опубликовано в: Breast Cancer Res Treat (2019)

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a rand...

по Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Опубликовано в: Breast Cancer Res Treat (2017)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

по Turner, N C, Finn, R S, Martin, M, Im, S -A, DeMichele, A, Ettl, J, Diéras, V, Moulder, S, Lipatov, O, Colleoni, M, Cristofanilli, M, Lu, D R, Mori, A, Giorgetti, C, Iyer, S, Bartlett, C Huang, Gelmon, K A
Опубликовано в: Ann Oncol (2018)